Medicines List

The product has not yet been released on the market.

Description

Eltrombopag Tchaikapharma contains eltrombopag, which belongs to a group of medicines called thrombopoietin-receptor antagonists. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding.

Indications

Eltrombopag Tchaikapharma is used to treat a bleeding disorder called immune (primary) thrombocytopenia (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.

Eltrombopag Tchaikapharma can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment.

Subject to medical prescription.

Concentration and pharmaceutical form: 25 mg film-coated tablets

Description

Tadalafil-Tchaikapharma contains the active substance tadalafil, which belongs to a group of medicines known as phosphodiesterase type 5 inhibitors. Tadalafil improves blood flow by relaxing the smooth muscle of blood vessels. This results in improved erectile function and relief of urinary symptoms associated with benign prostatic hyperplasia. Tadalafil Tchaikapharma is not intended for use in women.

Indications

Tadalafil-Tchaikapharma is indicated in adult men for:

• treatment of erectile dysfunction, characterized by the inability to achieve or maintain an erection sufficient for sexual activity;
• treatment of urinary symptoms associated with benign prostatic hyperplasia, such as difficulty in urination, sensation of incomplete bladder emptying and increased frequency of urination, including during the night.

Subject to medical prescription.

Concentration and pharmaceutical form: 5 mg; 10 mg; 20 mg film-coated tablets

The product has not yet been released on the market.

Description

Linagliptin/Metformin Tchaikapharma contains the active substances linagliptin and metformin and belongs to the group of medicines used for the treatment of type 2 diabetes mellitus. Linagliptin increases insulin secretion and reduces blood glucose levels, while metformin decreases glucose production in the body and improves insulin sensitivity. Their combined action helps to achieve effective blood glucose control.

Indications

Linagliptin/Metformin Tchaikapharma is indicated in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control:

• in patients who have not achieved adequate glycemic control with the maximum tolerated dose of metformin administered as monotherapy;
• in combination with other medicinal products for the treatment of diabetes, including insulin, in patients who have not achieved adequate glycemic control with metformin and these medicinal products;
• in patients already treated with a combination of linagliptin and metformin administered as separate tablets.

Subject to medical prescription.

Concentration and pharmaceutical form: 2,5 mg /850 mg; 2,5 mg /1000 mg film-coated tablets

The product has not yet been released on the market.

Description

Endora contains the active substance edoxaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming. It works by blocking the activity of factor Xa, which is an important component of blood clotting.

Indications

Endora is indicated in prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).

Subject to medical prescription.

Concentration and pharmaceutical form: 30 mg, 60 mg tablets